A VISIONaerie® approach
We discover, develop, and commercialize first-in-class therapies for the treatment of patients with glaucoma, dry eye, retinal diseases and other diseases of the eye
News Highlights
Aerie Pharmaceuticals Announces U.S. Food and Drug Administration Approval ... Aerie Pharmaceuticals Reports Second Quarter 2020 Financial Results and Pro... Aerie Pharmaceuticals Reports Positive Topline Results for AR-1105 (Dexamet...STOCK Quote
NASDAQ: AERI
$11.57USD
Sep 21, 4:00 PM ET
VOLUME
479,116
DAY LOW/HIGH
$11.30/$12.01
52 - WEEK LOW/HIGH
$10.22/$26.26
